Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Dermatologic Clinics
|
October 1, 1991
Immunotherapy of malignant melanoma
R Oratz, J C Bystryn
American Journal of Clinical Oncology
|
August 26, 1998
Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma
M A Rosenthal, R Oratz
International Archives of Allergy and Applied Immunology
|
January 1, 1979
Humoral mediator of antigenic competition demonstrated in vivo
S Zolla-Pazner, C Koehne, R Oratz
Investigational New Drugs
|
June 9, 1999
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687)
H Hochster, R Oratz, D S Ettinger, et al.
Journal of the National Cancer Institute
|
February 5, 1998
Identification of melanoma antigens that are immunogenic in humans and expressed in vivo
J Applebaum, S Reynolds, J Knispel, et al.
Cancer
|
March 1, 1992
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma
J C Bystryn, R Oratz, D Roses, et al.
Cancer Journal (Sudbury, Mass.)
|
January 5, 2002
Elective radiation therapy for high-risk malignant melanomas
J S Cooper, W S Chang, R Oratz, et al.
Journal of Biological Response Modifiers
|
August 1, 1989
Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine
R Oratz, C Cockerell, J L Speyer, et al.
Vaccine
|
April 1, 1995
Effect of DETOX as an adjuvant for melanoma vaccine
N Schultz, R Oratz, D Chen, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1992
Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor
C Walsh, R H Blum, R Oratz, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Dermatologic Clinics
|
October 1, 1991
Immunotherapy of malignant melanoma
R Oratz, J C Bystryn
American Journal of Clinical Oncology
|
August 26, 1998
Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma
M A Rosenthal, R Oratz
International Archives of Allergy and Applied Immunology
|
January 1, 1979
Humoral mediator of antigenic competition demonstrated in vivo
S Zolla-Pazner, C Koehne, R Oratz
Investigational New Drugs
|
June 9, 1999
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687)
H Hochster, R Oratz, D S Ettinger, et al.
Journal of the National Cancer Institute
|
February 5, 1998
Identification of melanoma antigens that are immunogenic in humans and expressed in vivo
J Applebaum, S Reynolds, J Knispel, et al.
Cancer
|
March 1, 1992
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma
J C Bystryn, R Oratz, D Roses, et al.
Cancer Journal (Sudbury, Mass.)
|
January 5, 2002
Elective radiation therapy for high-risk malignant melanomas
J S Cooper, W S Chang, R Oratz, et al.
Journal of Biological Response Modifiers
|
August 1, 1989
Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine
R Oratz, C Cockerell, J L Speyer, et al.
Vaccine
|
April 1, 1995
Effect of DETOX as an adjuvant for melanoma vaccine
N Schultz, R Oratz, D Chen, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1992
Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor
C Walsh, R H Blum, R Oratz, et al.
Page
of 3